EVALUATION OF RESIDUAL LEVONORGESTREL AS POTENTIAL BIOEQUIVALENCE METRIC FOR A LONG ACTING INTRAUTERINE SYSTEM USING QUANTITATIVE MODELING AND SIMULATION APPROACH

Satish Sharan, Ph.D.
Division of Quantitative Methods and Modeling
Office of Research and Standards
Office of Generic Drugs
Center for Drug Evaluation and Research, FDA

AAPS, Webinar
October 12th, 2017

Disclaimer

The opinions expressed in this presentation are those of the speaker and may not reflect the position of the U. S. Food and Drug Administration

Acknowledgement

OGD/ORS

- Xinyuan Zhang
- Lanyan Fang
- Yuan Zou
- Yan Wang
- Myong-Jin Kim
- Liang Zhao
- Stephanie Choi
- Lei Zhang
- Rob Lionberger

OTS/OB/DBVIII

- **Sungwoo Choi, Ph.D.**
- Fairouz Makhlouf
- Stella Grosser

Background

- Levonorgestrel (LNG) Intrauterine System (IUS): Progestin containing intrauterine system indicated for:
  - Intrauterine contraception for up to 5 years
  - Treatment of heavy menstrual bleeding for women who choose to use intrauterine contraception as their method of contraception
- T-body: 52 mg levonorgestrel
- Initial release rate of about 20 mcg/day which is reduced by about 50 % after 5 years.



- Approved: US (2000)
- Patent EXP: Dec 05, 2015

Challenges With Conventional PK Based BE Approach

- Due to local delivery of levonorgestrel, a conventional pharmacokinetic (PK)-based bioequivalence (BE) approach might not be relevant.

- In addition, considering that this product is designed to deliver LNG up to 5 years, a clinical endpoint bioequivalence study lasting for 5 years may not be practically feasible.

- Accordingly, explored alternative BE study designs that involve product physicochemical characterizations and a short term BE study.

- The current presentation assesses BE metrics and statistical criteria, using quantitative modeling and simulation approaches, for the alternative in vivo BE approaches for generic LNG IUS.

Residual LNG as Potential Alternative BE Metric

- LNG IUS's local action and practical limitation with direct measurement of LNG at the site of action.

- Residual LNG, which directly relates to the absolute amount of LNG delivered while inserted, was evaluated as a potential alternative BE metric for BE determination of LNG IUS.

- We evaluated 90 % confidence intervals (CI) on residual LNG at time points up to 5 years.

- Our analysis suggests that a BE limit of 95-105.26% for residual LNG at one-year (12 M post insertion) can ensure that residual LNG amount at five year is within BE limit of 80 – 125 %.

Data And Quantitative Model

- Residual Levonorgestrel (LNG) data from an array of IND and NDAs with study durations of 1, 3, and 5 years

- Time course of Residual LNG was explained using:

$$\boldsymbol{Residual\ LNG = A \cdot e^{-k \cdot t}}$$

$A = A\ constant\ representing\ LNG\ content\ (mg) at\ t = 0$

$k = First\ order\ constant\ (day^{-1})$

$t = time\ (days)$

Model Assumptions

- Product Specification: The initial content of Levonorgestrel was assumed to be between 47 – 57 mg/system.

- Virtual population incorporating the variability, under following assumptions:
  1. CV of 3% for A (mean 52 mg) provided a range of initial LNG in 47 – 57 mg/system.

  2. For release rate constant different CVs (i.e. 5 %, 10% and 15%) for k were tested and a CV of 10 % with a mean release rate constant of 4.2×10^{-4} per day provided a reasonable explanation of observed residual LNG.

Residual LNG from Virtual Population (n = 1000) and Observed data



Study Design

- Hypothetical generic test products with release rate constants differing by 5% up to 100% (δ) as compared to RLD were generated (i.e. $\mu_R \pm \delta \times \mu_R$)

- BE analysis was performed on residual LNG from virtual subjects (n = 20) for RLD and hypothetical generics using 80% - 125% BE limit.

- Then 90% confidence interval of geometric mean ratio of the RLD and TEST at 1 year and 5 years were computed and the procedure was repeated 20,000 times simulating 20,000 studies.

Parallel BE Study Results at 1 Year and 5 Year for Hypothetical Generics with Faster Release

		$\mu_R + \delta\mu_R$	
δ (%)		**1 Year**	**5 Years**
0 (0%)	**GMR (Lower, Upper)**	100.00 (98.47, 101.56)	100.03 (95.90, 104.35)
0.05 (5%)	**GMR (Lower, Upper)**	99.25 (97.72, 100.80)	96.33 (92.26, 100.58)
0.1 (10%)	**GMR (Lower, Upper)**	98.50 (96.97, 100.05)	92.74 (88.73, 96.92)
0.2 (20%)	**GMR (Lower, Upper)**	97.02 (95.49, 98.58)	86.00 (82.11, 90.07)
0.4 (40%)	**GMR (Lower, Upper)**	94.14 (92.61, 95.70)	73.97 (70.32, 77.81)
0.6 (60%)	**GMR (Lower, Upper)**	91.34 (89.80, 92.90)	63.59 (60.17, 67.20)
0.8 (80%)	**GMR (Lower, Upper)**	88.61 (87.06, 90.18)	54.64 (51.46, 58.02)
1.0 (100%)	**GMR (Lower, Upper)**	85.97 (84.41, 87.56)	46.98 (44.02, 50.14)

Observed Residual LNG from Different Formulations and Model Simulated Residual LNG in Virtual Population with Hypothetical Generic Formulations



Parallel BE Study Results at 1 Year and 5 Year for Hypothetical Generics with Slower Release

		$\mu_R - \delta\mu_R$	
δ (%)		1 Year	5 Years
0 (0%)	GMR (Lower, Upper)	100.00 (98.46, 101.55)	100.01 (95.87, 104.32)
0.05 (5%)	GMR (Lower, Upper)	100.76 (99.23, 102.31)	103.87 (99.67, 108.25)
0.1 (10%)	GMR (Lower, Upper)	101.53 (100.00, 103.08)	107.89 (103.62, 112.33)
0.2 (20%)	GMR (Lower, Upper)	103.06 (101.52, 104.62)	116.29 (111.88, 120.87)
0.4 (40%)	GMR (Lower, Upper)	106.24 (104.69, 107.82)	135.39 (130.65, 140.31)
0.6 (60%)	GMR (Lower, Upper)	109.50 (107.92, 111.10)	157.44 (152.26, 162.79)
0.8 (80%)	GMR (Lower, Upper)	112.86 (111.24, 114.49)	183.10 (177.32, 189.07)
1.0 (100%)	GMR (Lower, Upper)	116.32 (114.67, 118.00)	213.00 (206.37, 219.86)

Observed Residual LNG from Tested Formulations and Model Simulated Residual LNG in Virtual Population with Hypothetical Generic Formulations



Selection of Potential BE Limit at One Year

- Purpose of this approach was to find BE limit at one year which will ensure similar passing rate at 5 years, assuming conventional 80% - 125% BE criteria applied to residual LNG at 5 years.

- Then 90% confidence interval of geometric mean ratio of the RLD and TEST at 1 year and 5 years were computed and the procedure was repeated 20,000 times simulating 20,000 studies.

Selection of Potential BE Limit at One Year



n = 20, CV(A) = 3%, CV(k) = 10%

- BE Limit of 95 – 105.26 for Residual LNG at 1 year can be proposed to ensure BE limit of 80 – 125 at 5 year.

Evaluation of the Proposed (95% – 100/0.95%) BE Criteria at 1 Year

- Observed residual LNG data at one year was retrieved and parallel BE comparison was conducted.
- Residual LNG data in between 330 to 390 days were considered for one year analysis.
- Two cases were evaluated and BE analysis showed that criteria were met:
  - Formulation C vs formulation D
  - Formulation D vs Similar product

Evaluation of the Proposed (95% – 100/0.95%) BE Criteria at 1 Year

- Results from parallel BE study comparing 1 Year observed Residual LNG data of Formulation C and Formulation D.

TIME	GMR	Lower	Upper
1 Year	99.54	97.47	101.64

- Results parallel BE study comparing 1 Year observed Residual LNG data of Formulation D and Similar product.

TIME	GMR	Lower	Upper
1 Year	100.50	98.04	103.02

Summary

- Modeling and simulation was used to assess potential BE metrics and statistical criteria for a 5-year LNG IUS.

- Our analysis suggests that having 90% CI of that the residual LNG amount at first one-year (12 M post insertion) is within 95-105.26% can ensure that residual LNG amount at five year is within 80 – 125 %.

- A one year in vivo BE study would significantly shorten product development time and could potentially encourage generic competition in the LNG IUS product category.


FDA
U.S. FOOD & DRUG
ADMINISTRATION